Physician profile
Taylor E Benson
NPI 1831704733
$1,691.52
in general payments reported to CMS, 2019-2025
26 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.48 · 2022: $479 · 2023: $582 · 2024: $280 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $262.14 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $219.00 | 2021-2025 | Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $157.93 | 2022 | |
| Pfizer INC. | $131.26 | 2023-2024 | |
| Abbvie INC. | $114.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $105.48 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $100.98 | 2024-2025 | |
| Exact Sciences Corporation | $59.60 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.49 | 2022-2023 | Jardiance |
| Amgen INC. | $56.06 | 2023 | Repatha, Otezla |
| Tris Pharma INC | $53.59 | 2023 | Dyanavel Xr |
| Dexcom, INC. | $46.93 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $43.09 | 2024 | Erleada |
| Glaxosmithkline, LLC. | $42.53 | 2023-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $35.64 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $27.53 | 2024 | Korlym |
| Inspire Medical Systems, INC. | $23.57 | 2025 | Inspire |
| Almatica Pharma LLC | $23.27 | 2022 | |
| Ibsa Pharma INC. | $20.33 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.97 | 2024 | Recorlev |
| Phadia US INC. | $18.95 | 2023 | Immunocap |
| Medtronic, INC. | $15.89 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.86 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.90 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $13.61 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $13.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.